董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michelle Pernice | 女 | Director | 38 | 未披露 | 未持股 | 2026-11-09 |
| Todd Shegog | 男 | Director | 61 | 未披露 | 未持股 | 2026-11-09 |
高管介绍
暂无数据
董事简历
中英对照 | 中文 | 英文- Michelle Pernice
-
Michelle Pernice自2026年5月起担任Mentari董事会成员。Pernice女士是医疗保健投资公司Fairmount Funds Management LLC的运营合伙人。在2023年10月加入Fairmount之前，Pernice女士曾在多家制药和生物技术公司担任全球监管职务，包括2021-2023年的Pardes Biosciences、2019-2021年的商业阶段生物制药公司德纳维制药 Technologies Corp.、2014-2019年的全球生物技术公司安进公司TERM2TERM1（纳斯达克：AMGN）以及2012-2014年的全球制药公司Novartis AG（NYSE：NVS），包括跨越所有发展阶段、多种模式以及值得注意的批准的发展战略。Pernice女士获得了圣约翰大学的药学博士学位，并通过罗格斯大学完成了后药学博士奖学金。Pernice女士自2024年11月起担任Korsana Biosciences，Inc.（纳斯达克：KRSA）的董事。
Michelle Pernice has served as a member of the Mentari Board since May 2026. Ms. Pernice is an Operating Partner at Fairmount Funds Management LLC, a healthcare investment firm. Prior to joining Fairmount in October 2023, Ms. Pernice served in global regulatory roles for numerous pharmaceutical and biotechnology companies, including Pardes Biosciences from 2021 to 2023, Dynavax Technologies Corp., a commercial stage biopharmaceutical company, from 2019 to 2021, Amgen Inc. (Nasdaq: AMGN), a global biotechnology company, from 2014 to 2019, and Novartis AG (NYSE: NVS), a global pharmaceutical company, from 2012 to 2014, including development strategy across all phases of development, multiple modalities, and notable approvals. Ms. Pernice received her PharmD from St. John's University and completed a post PharmD fellowship through Rutgers University. Ms. Pernice has served as a director of Korsana Biosciences, Inc. (Nasdaq: KRSA) since November 2024. - Michelle Pernice自2026年5月起担任Mentari董事会成员。Pernice女士是医疗保健投资公司Fairmount Funds Management LLC的运营合伙人。在2023年10月加入Fairmount之前，Pernice女士曾在多家制药和生物技术公司担任全球监管职务，包括2021-2023年的Pardes Biosciences、2019-2021年的商业阶段生物制药公司德纳维制药 Technologies Corp.、2014-2019年的全球生物技术公司安进公司TERM2TERM1（纳斯达克：AMGN）以及2012-2014年的全球制药公司Novartis AG（NYSE：NVS），包括跨越所有发展阶段、多种模式以及值得注意的批准的发展战略。Pernice女士获得了圣约翰大学的药学博士学位，并通过罗格斯大学完成了后药学博士奖学金。Pernice女士自2024年11月起担任Korsana Biosciences，Inc.（纳斯达克：KRSA）的董事。
- Michelle Pernice has served as a member of the Mentari Board since May 2026. Ms. Pernice is an Operating Partner at Fairmount Funds Management LLC, a healthcare investment firm. Prior to joining Fairmount in October 2023, Ms. Pernice served in global regulatory roles for numerous pharmaceutical and biotechnology companies, including Pardes Biosciences from 2021 to 2023, Dynavax Technologies Corp., a commercial stage biopharmaceutical company, from 2019 to 2021, Amgen Inc. (Nasdaq: AMGN), a global biotechnology company, from 2014 to 2019, and Novartis AG (NYSE: NVS), a global pharmaceutical company, from 2012 to 2014, including development strategy across all phases of development, multiple modalities, and notable approvals. Ms. Pernice received her PharmD from St. John's University and completed a post PharmD fellowship through Rutgers University. Ms. Pernice has served as a director of Korsana Biosciences, Inc. (Nasdaq: KRSA) since November 2024.
- Todd Shegog
-
自首次生效之日起，Todd Shegog将被任命为合并后公司董事会成员。Shegog先生在生物技术和制药行业拥有30多年的财务、运营、公司战略和合规专业知识。于2019年9月至2022年10月被诺和诺德收购期间担任临床阶段生物制药公司Forma Therapeutics，Inc.（原，纳斯达克：FMTX）高级副总裁兼首席财务官。在加入Forma Therapeutics之前，Shegog先生曾在临床阶段生物制药公司Synlogic, Inc.（纳斯达克：SYBX）担任首席财务官的TERM1，在那里他于2016年9月至2019年9月指导公司的财务战略和管理以及设施和信息系统。2014年4月至2016年8月，Shegog先生在Forum Pharmaceuticals，Inc.担任高级副总裁兼首席财务官，Forum Pharmaceuticals，Inc.是一家早期生物制药公司，在他们寻求精神分裂症和阿尔茨海默病的创新疗法期间，他负责财务、运营和信息系统。他还曾在Millennium Pharmaceuticals，Inc.（现为Takeda Oncology）担任首席财务官，于1998年至2014年期间负责管理公司的财务资源、企业规划、财务报告和合规工作。Shegog先生在拉斐特学院获得电气工程学士学位，在卡内基梅隆大学泰珀管理学院获得工商管理硕士学位。Shegog先生自2021年2月起担任Cogent Biosciences, Inc.（纳斯达克：COGT）的董事。
Todd Shegog will be appointed as a member of the Combined Company board of directors as of the First Effective Time. Mr. Shegog has more than 30 years of financial, operations, corporate strategy and compliance expertise in the biotechnology and pharmaceutical industries. He served as Senior Vice President and Chief Financial Officer of Forma Therapeutics, Inc. (formerly, Nasdaq: FMTX), a clinical stage biopharmaceutical company, from September 2019 through its acquisition by Novo Nordisk in October 2022. Prior to Forma Therapeutics, Mr. Shegog served as Chief Financial Officer of Synlogic, Inc. (Nasdaq: SYBX), a clinical stage biopharmaceutical company, where he directed the company's financial strategy and management as well as facilities and information systems from September 2016 to September 2019. From April 2014 to August 2016, Mr. Shegog served as Senior Vice President and Chief Financial Officer at Forum Pharmaceuticals, Inc., an early stage biopharmaceutical company, where he was responsible for finance, operations and information systems during their pursuit of innovative therapies for schizophrenia and Alzheimer's disease. He also served as the Chief Financial Officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company's financial resources, corporate planning, financial reporting and compliance from 1998 to 2014. Mr. Shegog earned a B.S. in Electrical Engineering from Lafayette College and an M.B.A. from the Tepper School of Management at Carnegie Mellon University. Mr. Shegog has served as a director of Cogent Biosciences, Inc. (Nasdaq: COGT) since February 2021. - 自首次生效之日起，Todd Shegog将被任命为合并后公司董事会成员。Shegog先生在生物技术和制药行业拥有30多年的财务、运营、公司战略和合规专业知识。于2019年9月至2022年10月被诺和诺德收购期间担任临床阶段生物制药公司Forma Therapeutics，Inc.（原，纳斯达克：FMTX）高级副总裁兼首席财务官。在加入Forma Therapeutics之前，Shegog先生曾在临床阶段生物制药公司Synlogic, Inc.（纳斯达克：SYBX）担任首席财务官的TERM1，在那里他于2016年9月至2019年9月指导公司的财务战略和管理以及设施和信息系统。2014年4月至2016年8月，Shegog先生在Forum Pharmaceuticals，Inc.担任高级副总裁兼首席财务官，Forum Pharmaceuticals，Inc.是一家早期生物制药公司，在他们寻求精神分裂症和阿尔茨海默病的创新疗法期间，他负责财务、运营和信息系统。他还曾在Millennium Pharmaceuticals，Inc.（现为Takeda Oncology）担任首席财务官，于1998年至2014年期间负责管理公司的财务资源、企业规划、财务报告和合规工作。Shegog先生在拉斐特学院获得电气工程学士学位，在卡内基梅隆大学泰珀管理学院获得工商管理硕士学位。Shegog先生自2021年2月起担任Cogent Biosciences, Inc.（纳斯达克：COGT）的董事。
- Todd Shegog will be appointed as a member of the Combined Company board of directors as of the First Effective Time. Mr. Shegog has more than 30 years of financial, operations, corporate strategy and compliance expertise in the biotechnology and pharmaceutical industries. He served as Senior Vice President and Chief Financial Officer of Forma Therapeutics, Inc. (formerly, Nasdaq: FMTX), a clinical stage biopharmaceutical company, from September 2019 through its acquisition by Novo Nordisk in October 2022. Prior to Forma Therapeutics, Mr. Shegog served as Chief Financial Officer of Synlogic, Inc. (Nasdaq: SYBX), a clinical stage biopharmaceutical company, where he directed the company's financial strategy and management as well as facilities and information systems from September 2016 to September 2019. From April 2014 to August 2016, Mr. Shegog served as Senior Vice President and Chief Financial Officer at Forum Pharmaceuticals, Inc., an early stage biopharmaceutical company, where he was responsible for finance, operations and information systems during their pursuit of innovative therapies for schizophrenia and Alzheimer's disease. He also served as the Chief Financial Officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company's financial resources, corporate planning, financial reporting and compliance from 1998 to 2014. Mr. Shegog earned a B.S. in Electrical Engineering from Lafayette College and an M.B.A. from the Tepper School of Management at Carnegie Mellon University. Mr. Shegog has served as a director of Cogent Biosciences, Inc. (Nasdaq: COGT) since February 2021.